CB 300919 50mg

CB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft

Price Not Available 50mg CB 300919 50mg Supplier Page

Trivial name	CB 300919 50mg
Catalog Number	A11359-50
Alternative Name(s)	4-[[[7-Chloro-3,4-dihydro-3-methyl-2-[(4-methyl-1-piperazinyl)methyl]-4-oxo-6-quinazolinyl]methyl]-2-propyn-1-ylamino]-N-(3-pyridinylmethyl)benzamide
Molecular Formula	C32H34ClN7O2
CAS#	289715-28-2
SMILES	CN1CCN(CC1)CC2=NC3=CC(=C(C=C3C(=O)N2C)CN(CC#C)C4=CC=C(C=C4)C(=O)NCC5=CN=CC=C5)Cl
Size	50mg
Supplier Page	http://www.adooq.com/cb-300919.html